

# Index

- ABCE models 18
- Abuja Goals Fund *see* AGF
- AD (auto-disposable syringes) 81, 83  
transmission probability 83
- Addis Ababa conference *see* Civil Society Panel
- Addis Ababa Youth Forum Prioritization 347
- adolescent sexual activity 239, 241, 245, 251–2, 254, 258,  
260–1, 269–70, *see also* keeping girls in school
- Afrobarometer project 227, 230–1, 232
- age factors 20–1
- AGF (Abuja Goals Fund) 6, 183, 184, 186, 201–5, 206,  
222, 229–33, 344, 346, 347
- AIDS  
deaths averted costs 306–7  
denial by politicians 234, 235  
epidemiology 301  
funding 342  
future scenarios 304–5  
R&D *see* vaccine research and development  
retro-virus discovered 61, *see also* ART  
trials 314–18  
vaccine 7
- AIDS in the Twenty-First Century: Disease and  
Globalisation* 68
- AIDS: Taking a Long-Term View* 2
- AIDS vaccine  
accelerating development 309–12, 346, 347  
access to 325  
alternatives to 326  
benefit-cost ratios 310, 321, 326  
benefits 309  
costs 305–6, 321, 322–3  
in sub-Saharan Africa 306  
disinhibition 146, 324–5  
effectiveness 323–4  
and epidemic future 324  
paying for 325–6  
research 330  
societal benefits 321  
synergistic benefits 325
- aids2031 Consortium xx, 2  
Modeling Working Group xix
- AIDSCost projection program 128, 147
- AIM (AIDS Impact Model) 78–9, 89–90, 96–7
- alcohol  
abuse as HIV epidemic driver 285
- Laffer Curve 244  
problematic use of 239, 242–5  
substitution 244  
taxation 241, 243, 247, 250–1, 254, 257, 261, 262–3,  
267, 268, 269–70, 293, 295–6, 346, 347, 348
- Angola  
alcohol tax 262–3  
blood supply testing 86  
HIV epidemic scale 65–6  
HIV incidence/prevalence 13  
key indicators 115–16
- anthropometric outcomes 55
- Appel, Jacob 191
- ART (anti-retroviral treatment)  
access to treatment 125, 140–1, 181, 185, 233–4  
AIDSCost projection program 128, 147  
anti-retroviral prophylaxis options 109–10, 122  
at-risk groups targeting strategy 312  
and behavioral responses 50–1  
benefit-cost analyses  
for successful infection prevention treatment 159–60  
for unsuccessful infection prevention treatment 156  
benefit-cost ratios 76, 77–8, 137, 138–9, 143, 145,  
178–82  
benefit-cost results 141–2, 146–8  
best treatment stage 125–6  
CD4 cells 110–12, 125–6, 127–30, 136, 137–9, 141–2,  
143–4, 156, 160, 178  
CD4 counts and eligibility 181  
cost-effectiveness 141–2  
costs 32, 77, 126–7, 145, 169, 178  
coverage 128  
and family planning 222  
drug costs 308  
and dynamics of HIV infection 103–4  
eligibility guidelines 213–14  
extension of 15  
feedback effects 219–20  
future cost per patient 178–9  
historical counterfactual 135  
HIV transmission models 79–81, 131–3  
incremental spending 140  
infections reduction incremental benefits 194  
life years gained 179–81, 184  
lifelong treatment 109–10, 112  
mother-to-child infections 75

- national uptake rate 128
- Nobel Laureate Economist Expert Panel findings on 339
- non-AIDS mortality rate 180
- numbers treated by 1
- oral 301
- patient life expectancy 138–9
- and prevention techniques 70
- primary infection prevention 159
- scaling-up benefits 181, 346, 347
- scaling-up enrollment 343, 347–8
- secondary infection prevention 159
- simulated scenarios 135–7
- spillover benefits 145
- statistics provision 79
- in sub-Saharan Africa xix
- sufficient damage factor 127
- survival years 180–1
- TDF/FTC combination 54
- test-and-treat strategy 12–14, 18, 19–20, 22–3, 25, 53–4, 58, 112, 192
- topical 301
- topical microbicides 238
- treatment cost per person/year 135, 173–4
- treatment criteria 128
- treatment dynamics modeling 127–30
- treatment eligibility 334
- treatment emergence 125
- treatment impact modeling 130–3, 142–5
- treatment unit costs 133–5
- treatment uptake rate modeling 128–30
  - impact of 135
- uptake projection 139–40
- value of lives saved 78
- zero uptake 135, 136
  - and benefit-cost ratios 151
  - simulation results 139
- ARV (anti-retroviral prophylaxis regimen) 109–10, 135, 160–3, 172–3, 175–6
  - adverse side effects 174
  - and AIDS vaccine 305
  - benefit-cost ratio 173
  - cost decline 179
  - deployment of 146
  - potential cost reduction 179
- Aryeetey, Ernest 337–8
- at-risk groups targeting strategy 312
- AVERT model 79–81
- AZT (Zidovudine) program 162
- B/C ratios, naive estimates of 155
- Baltussen, Rob 5
- Banerjee, Abhijit 191
- Barnett, Tony 6
- Bärnighausen, Till 6
- BCC (behavioral change communication) 16
- BCR *see* benefit-cost ratios
- behavioral prevention programs 14–15
- Behrman, Jere 4, 349
- benefit estimates 103–4
- benefit-cost analyses 21, 23
  - continued investment 308–9
  - DALYs (disability-adjusted life years) 20, 22, 26–9, 32–3, 34–40, 41–2, 49, 62, 226
  - decline in World Bank 190
  - dynamic framework time representation 155–60
  - HC (Human Capital) approach 170
  - HIV treatment pre-pregnancy 164–6
  - information campaigns (IC) 25–6
  - and interventions 108
  - life-cycle perspective 26, 30, 62
  - Nobel Laureate Economist Expert Panel findings on 337
  - for policy interventions 26–32
    - discounting 31
    - estimation challenges 31–2
    - general considerations 26–30
    - interaction among solutions 31
    - prices 30
    - range of costs 31
    - range of impacts 30
    - scale 31
  - pregnant women 167–8
  - and sets of objects 283
  - for successful infection prevention treatment 159–60
  - and unrecognized metaphors 281
  - for unsuccessful infection prevention treatment 156
  - vaccine research and development 304–9
  - WTP (willingness to pay) 170–1
- benefit-cost ratios 5, 36–7, 40–1, 181–2, 189
  - AIDS vaccine development 310
  - ART 32, 76, 77–8, 137, 138–9, 143, 145, 146–8, 178–82
  - and ARV provision 173
  - CCTs 220–2
  - CD4 cell count 158–60
  - community health 198
  - cross-country variations 293
  - discounted/undiscounted 156, 175
  - health system strengthening 208
  - HIV reduction interventions 34–7, 41–2, 63–4, 174, 293
  - infections averted 32
  - interventions 260–3
  - male circumcision 36–7, 40–1, 63–4, 339
  - pMTCT in sub-Saharan Africa 160–1, 163, 174–5
  - procedures summary 32–3
  - treatment costs 32
  - treatment as prevention 151
  - unit costs 294–5
  - varying average costs 294–5
  - VSL (Value of a Statistical Life) approach 170–1
- Benin
  - alcohol tax 262–3
  - blood supply testing 86
  - HIV incidence/prevalence 13, 114–17
  - key indicators 115–16
  - problems faced by government (Afrobarometer) 232

## 352 Index

- blockbuster drugs 303  
 blood safety intervention 186  
 blood transfusions 4, 74, 86–8, 89, 102–3, 346, 347  
 Bloom, David 5–6  
 BMGF (Bill and Melinda Gates Foundation) 213  
 body undergoing treatment metaphor 283–4  
 Bollinger, Lori 4, 102, 105, 121, 169–70, 171, 259, 347–8  
 Botswana  
   alcohol tax 262–3  
   health priority survey 230–1  
   HIV epidemic scale 65–6  
   HIV incidence/prevalence 12, 13, 29, 30, 34, 39–40  
   key indicators 115–16  
   life expectancy with/without AIDS 162  
   male circumcision 25, 40–1  
   problems faced by government (Afrobarometer) 232  
   resources allocated to 15–17  
   unmet need for family planning 165  
 Brandeau, M. L. 295  
 Brazil, AIDS vaccine 325  
 Brent, Robert 5  
 British Columbia Center for Excellence on HIV/AIDS 69–70  
 Burkina Faso  
   Abuja target 202  
   alcohol tax 262–3  
   HIV incidence/prevalence 13, 114–17  
   key indicators 115–16  
   life expectancy with/without AIDS 162  
   unmet need for family planning 165  
 Burundi  
   alcohol tax 262–3  
   HIV incidence/prevalence 13  
   key indicators 115–16  
   life expectancy with/without AIDS 162  
   unmet need for family planning 165  
 bush circumcisions 52  
  
 Cambodia, conditional cash transfers 254  
 Cameroon  
   alcohol tax 262–3  
   HIV incidence/prevalence 13  
   key indicators 115–16  
   life expectancy with/without AIDS 162  
   unmet need for family planning 165  
 Campbell Collaboration 65  
 cancer as investment priority 189  
 canine distemper, and vaccine research and development 313  
 Cape Verde, problems faced by government (Afrobarometer) 232  
 CAPRISA (Centre for the AIDS Programme of Research in South Africa) 64  
 CAPRISA Study 54  
 cash incentive programs *see* CCT  
 CBA (cost-benefit analysis) *see* benefit-cost analyses  
 CCT (conditional cash transfer) 21, 23, 31, 53, 54–8, 191–3, 218  
   benefit-cost ratios 220–2  
   conceptual foundations of 56  
   current evidence on 57–8  
   female education 245  
   and HIV awareness 192  
   and HIV testing 228–9  
   and infection reduction 222  
   and joint objectives 184  
   keeping girls in school *see* keeping girls in school  
   potential impacts of 186  
   rationale for 54–7  
   RESPECT study 193  
 CD4 cells 110–12, 125–6, 127–30, 136, 137–9, 141–2, 143–4, 156, 160, 172, 173, 178, 199  
   cell count and ART eligibility 181  
   cell count benefit-cost ratios 158–60  
   and death probability 180–1  
   point of care dipsticks 179  
   screening 161  
 CEA *see* cost-effectiveness analyses  
 Central African Republic  
   alcohol tax 262–3  
   health worker shortage 196  
   HIV incidence/prevalence 13, 196  
   key indicators 115–16  
   life expectancy with/without AIDS 162  
 Chad  
   alcohol tax 262–3  
   HIV incidence/prevalence 13  
   key indicators 115–16  
   unmet need for family planning 165  
 CHAHA program 248–9  
 childhood diseases, as investment priority 189  
 Chimeric Venezuelan Equine Encephalitis 313  
 China, conditional cash transfers (one-child policy) 191  
 CHWs (community health workers)  
   deployment 216, 218  
   Technical Task Force 186, 196, 197–9  
   training costs/benefits 220–2  
 circumcision *see* MC  
 Civil Society Panel 341, 349  
   Abuja Goals Fund 344  
   AIDS funding 342  
   ART (anti-retroviral treatment) scaled-up enrollment 343  
   CCT (conditional cash transfer) and keeping girls in school 343–4  
   keeping girls in school 343–4, *see also* keeping girls in school  
   mother-to-child transmission prevention (pMTCT) 342–3, 347–8  
   redefining priorities theme 341  
 CM (contingency management) 55–6  
 CMH (Commission on Macroeconomics and Health) 104, 195, 203  
 COD (cash on delivery)

- and Abuja Goals Fund (AGF) 201–5, 206, 229–33
- donor assistance 184
- to governments 218
- Collier, Paul 337–8
- combination prevention 145
- commodity approach to strategies 15
- community health workers 183, 184, 206, 207, 228
- community mobilization 248–9, 253, 255, 259, 265, 267, 268, 269–70, 293
- Community Systems Strengthening Framework 235
- Comoros
  - alcohol tax 262–3
  - HIV incidence/prevalence 13, 114–17
  - key indicators 115–16
- concurrent sexual partners, as HIV epidemic driver 285
- condoms 11, 19, 51, 56, 68, 170, 248
- Congo
  - Abuja target 202
  - alcohol tax 262–3
  - HIV incidence/prevalence 13, 114–17
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - unmet need for family planning 165
- contraception, unmet need for 164
  - see also* condoms; family planning
- Copenhagen Consensus 2–3, 7, 8, 71
- Copenhagen Consensus Center, global development project (2008) 2
- Copenhagen Consensus Challenge paper 245
- Copenhagen Consensus project (2004) 2
- cost-effectiveness xx, 11, 17–23, 37–9, 49, 58
  - blood transfusions 74, 86–8
  - ICER (incremental cost-effectiveness ratio) 75–6
  - injecting drug users 92–5
  - interventions 17–23, 242–5, 260
  - medical injections 74, 81–6
  - mother-to-child transmission 74, 121
  - in sub-Saharan Africa 11, 20, 104
- cost-effectiveness analyses 22, 283
  - and unrecognized metaphors 281
- cost estimates 103
- cost per death 194, 198
- cost per infection 104
- Cote d'Ivoire
  - alcohol tax 262–3
  - HIV incidence/prevalence 13, 114–17
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - OIs (opportunistic infections) 76–7, 78
  - unmet need for family planning 165
- cotrimoxazole prophylaxis 161
- couple-based HIV testing 20
- CRAG (cryptococcal antigen)
  - costs and benefits 186, 200–1, 208
  - testing 199–200, 201, 228
- critical enablers 188–9
- cross-intervention benefits 347
- cryptococcal meningitis (CM) 183, 200–1, 206, 216, 218, 220, 340
- Cryptococcosis neoformans 184, 199–201
- cultural practices, as HIV epidemic driver 285
- Cytomegalovirus Clinical Development Program 313
- DALYs (disability-adjusted life years) 20, 22, 26–9, 34–40, 41–2, 49, 62, 63–4, 75–6, 104, 170–1, 175–6, 189–90, 197, 200, 203, 205, 206, 207, 226, 243, 260, 263–5, 349
  - by country 271–2
  - incremental cost 274–5
  - parameters 260–1
- DCP2 190–1
- de Walque, Damien 4
- dead metaphors 282
- deaths averted 188–9, 194, 202, 203, 204, 306–7, 308
- DemProj software tool 78
- diagnostic tests 300
- discounting 171–2, 173, 175, 189–90, 200, 263, 333
- disinhibition 146, 324–5, 339
- Djibouti
  - Abuja target 202
  - key indicators 115–16
- DMPTT *see* Male Circumcision: Decision Makers' Program Planning Tool
- donor support flat-lining 213–14
- dose-response 284
- drug costs 126–7, 308
- drug development 300
- drug supply systems intervention 186
- drug users, injecting 92–5
- Duflo, Esther 191
- Earth Institute Technical Taskforce 195
- ecology of risk 285, 286
- The Economist*, end of AIDS? 12
- Efavirenz 111, 126
- effectiveness estimates 103–4
- efficiency solution 188
- embodiment of social conditions 287–8
- emergency rescue intervention 186
- epidemic model 295
- EPP (Estimation and Projection Package) 78
- Equatorial Guinea
  - alcohol tax 262–3
  - HIV incidence/prevalence 13
  - key indicators 115–16
- Eritrea
  - alcohol tax 262–3
  - HIV incidence/prevalence 13, 114–17
  - infant mortality 204
  - key indicators 115–16
  - life expectancy with/without AIDS 162
- Ethiopia
  - alcohol tax 262–3
  - HIV prevalence 12, 114–17, 296–7

## 354 Index

- Ethiopia (*cont.*)
- key indicators 115–16
  - life expectancy with/without AIDS 162
  - life insurance incentivization 296–7
  - Millennium Village Project (MVP) 247
  - PEPFAR-funded interventions 255
  - unmet need for family planning 165
  - Voices of the Poor* project 196
- evidence-based allocation strategy 17–18
- external validity of interventions 294
- faith-based abstinence 68
- family planning 97, 117, 161, 163–4, 197, 198, 202, 222
- cost-effectiveness of 164, 198–9
  - social benefits 164
  - unmet need for in sub-Saharan Africa 165
- Farm Input Subsidy Programme 247
- FDA, and microbicide 64
- FEM-PrEP trial 54
- female education 245
- female sex workers 296–7
- FFS (Farmer Field School) 247, 252
- first-line treatment benefits/costs 157
- flat-lining donor support 213–14
- Forsythe, Stephen 7
- funding 1
- alternative use for 214–15
  - competing demands 213–14
- G8 (Gleneagles 2005) 185
- Gabon
- alcohol tax 262–3
  - HIV incidence/prevalence 13
  - key indicators 115–16
  - life expectancy with/without AIDS 162
- Gambia
- alcohol tax 262–3
  - HIV incidence/prevalence 13
  - key indicators 115–16
- Gardasil 322, 323, 325
- Garnett, Geoffrey 5, 173–4, 178–82, 347–8
- GAVI Alliance 184–6
- gender inequalities, as HIV epidemic driver 285
- gender role perceptions/training 239, 240, 246–7, 248–9, 252, 254–5, 258–9, 263, 267, 269–70, 293
- general structure (GS) interventions 216–18, 221
- genital lesions 285
- Georgetown University Expert Panel *see* Nobel Laureate Economist Expert Panel
- GFATM *see* Global Fund to Fight AIDS, Tuberculosis and Malaria
- Ghana
- alcohol tax 262–3
  - health priority survey 230–1
  - HIV incidence/prevalence 13, 114–17
  - HIV/AIDS stigma 248–9
  - key indicators 115–16
  - problems faced by government (Afrobarometer) 232
  - sexually transmitted HIV 11
  - unmet need for family planning 165
  - Voices of the Poor* project 196
- girls in school 239, 241, 245, 251–2, 254, 258, 260–1, 267, 268, 269–70, 284, 343–4
- Gleneagles Summit (2006) 125
- Global Crises, Global Solutions* 184–5, 190
- Global Fund Forum 342
- Global Fund to Fight AIDS, Tuberculosis and Malaria (GFATM) 61, 182, 184–6, 189, 202–3, 213, 214–15, 230, 233–6, 346
- Global Fund-hosted Event Prioritization 346
- global political commitment, to fighting HIV 213
- Global Programme on AIDS 283
- GNI per capita statistical life value 189–90
- goal-directed thinking 288
- Goals and Allocation by Cost-Effectiveness (ABCE) models 18
- Goals Model/Goals Express 79–81, 93, 96–7, 259, 265
- Going Upstream: A Cost-Benefit Analysis of Social Policy Interventions to Enhance the HIV/AIDS Response in Sub-Saharan Africa* 282–3
- going upstream metaphor 282–3
- Granich, Reuben M. 69–70, 191–2
- GS (general structure) interventions 216–18, 221
- Guinea
- alcohol tax 262–3
  - HIV incidence/prevalence 13, 114–17
  - key indicators 115–16
- Guinea-Bissau
- alcohol tax 262–3
  - HIV incidence/prevalence 13
  - key indicators 115–16
  - life expectancy with/without AIDS 162
- Gupta, Geeta Rao 286
- Halperin, D. T. 19
- HCT *see* HTC
- health benefits, advances in estimating 190–1
- health care costs, and HIV prevention 307
- health care reform, political legitimacy of 231–3
- health center upgrade/construction intervention 186
- health inequalities and environments 287
- health priority survey 230–1
- health services strengthening, in rural areas 196–7
- health services upgrade 195–9
- health spending ratios 187
- health system capacity 226–8
- health system infrastructure and pMTCT 117–18
- health system intervention evaluation 215–17
- benefits evaluation 216–17
  - costs 217
  - feasibility 215
  - flexibility 215
  - intervention level/scope 216

- technical efficiency 215
- time lags/certainty levels 217–18
- health system strengthening 213–23, 226–36
  - access improvement 228
  - benefit evaluation 216–18
  - challenges
  - cost-benefit ratio 208
  - cost evaluation 217–18
  - feasibility 215
  - flexibility 215
  - intervention evaluation 215–16, 217
  - intervention scope 216
  - life year value monetization 226
  - methodological issues 226–33
  - Nobel Laureate Economist Expert Panel findings on 340
  - structures 214–15
- health workers
  - shortage 196
  - skills upgrade 195–9
  - staff expansion 197–9
- heart attacks, as investment priority 189
- Hecht, Robert 7
- herpes
  - as epidemic driver 285
  - and Stepping Stones 246
- heterosexual HIV transmission 303
- HIA (HIV infection averted) 63–4
- high-risk groups 153, 155
- HIPC (highly indebted poor countries) initiative 202–3
- historical counterfactual 135
- HIV
  - and alcohol consumption 242
  - in couples 126, 159
  - deaths statistics xix, 153, 299
  - dynamic models of effect on 152–5
  - epidemic drivers 285
  - epidemic scale 65–6
  - fatality rate 125
  - global political commitment to fighting 213
  - hope and social intervention 288–90
  - impact modeling 255–9
  - incidence (of infection) 131
  - incidence/prevalence ratio 146–8, 213, 226–8
  - infections averted 255–9, 271–2
  - modes of transmission 66–7
  - POC (point-of-care) diagnostic tests 119–21
  - in women in sub-Saharan Africa 172–3
  - see also* vaccine research and development
- HIV counseling, universal 183
- HIV information, universal 183
- HIV prevention, as investment priority 189
- HIV programs, demand side 218
- HIV testing
  - monetization 229
  - universal 183, 228–9
- HIV transmission
  - heterosexual 303
  - models 79–81, 131–3
  - rate estimation 151
  - in sub-Saharan Africa 238
  - susceptibility and income inequality 287
- HIV treatment
  - for all women 164–6
  - benefits of prevention 306–8
  - costs 70
  - efficiency 215
  - immediacy 70
  - individual effects 70
  - population effects 70
  - programs' integration with primary health care 214–15
  - selective expansion 214–15
  - selective integration 214–15
  - stand-alone programs 215
  - see also* ART (anti-retroviral treatment); HSS (health system strengthening)
- HIV vulnerability, social drivers 239
- HIV-infected children, survival rate 77
- HIV/AIDS
  - disease statistics 200
  - R&D *see* vaccine research and development
  - social policy interventions 281–90
  - spending and health systems strengthening 186–7
- HIVNS (HIV-focused non-structural) interventions 216–18, 221
- HLT (High Level Taskforce on International Innovative Financing for Health Systems) 185, 195, 202–3
- Hontelez, Jan 5
- hope
  - analytical advantages 289
  - as diagnostic tool 289–90
  - and income 289
  - and optimism 288
  - and palliative care 289
  - and social intervention 288–90
- HSS (health systems strengthening) 184, 186–7, 204–5
  - expansion of 214–15
  - and health worker skills upgrade 195–9
  - intervention scale 219
  - interventions implementation time 219
  - potential of 215
  - priority setting 220
  - targeting vulnerable populations 220
  - unintended consequences 218–19
- HTC (HIV testing and counseling) 14–15, 19–20, 22–3, 25, 41–2
  - benefits of 49–50, 62–3
  - and Civil Society Panel 344
  - cost-benefit ratio 63–4
  - cost-effectiveness 37
  - costs of 33–4
  - and HIV incidence 33–4
  - as prevention 69–70, 192–3
  - treatment as prevention 166–8
  - uptake at community level 248

## 356 Index

- Humair, Sal 6
- human resources training intervention 186
- human rights and conditional cash transfers 191
- hyperbolic discounting 190
- IAVI (International AIDS Vaccine Initiative) 299, 305–6  
research developments source 313
- IC (information campaigns) 20, 25–6, 34, 41–2, 49–50,  
52–3, 62, 63–4, 70–1
- ICASA 341, 346
- ICD (infectious and communicable diseases) 188
- ICER (incremental cost-effectiveness ratio) 75–6
- IDU (injecting drug use) interventions 92–5, 96, 102–3,  
104, 105
- IeDEA Consortium 180
- IHP+ (International Health Partnerships) 184–5, 195,  
202–3, 204–5
- IMAGE (Intervention with Microfinance for AIDS and  
Gender Equity) 21, 246, 247, 252, 254–5, 258–9
- immunodeficiency virus 20–1
- impact evaluations 50
- inappropriate metaphors 281–8
- income inequality and poverty/transmission susceptibility  
287
- incremental benefits 194
- incremental spending results 140
- India, conditional cash transfers (vasectomy grants) 191
- individual behavior  
environment as regulator of 286–7  
and risk environments 286
- infant HIV exposure diagnosis 161
- infant infections 188, 198
- infant lives saved 207
- infant mortality 203, 204
- infants, as most valued lives 190
- infection probability model 79–81
- information technology intervention 186
- initiation schools 52
- injecting drug users 75, 92–5
- Institute for Health Metrics and Evaluation 332
- intergenerational sexual behavior as HIV epidemic driver  
285
- intergenerational transmission of disease 33, 285
- International Conference on AIDS (ICASA) 341, 346
- International Group on Analysis of Trends in HIV  
Prevalence and Behaviors in Young People in  
Countries most Affected by HIV (2010) 19
- International HIV/AIDS Alliance 248–9
- interventions  
adolescent sexual activity 239, 241, 245, 247, *see also*  
keeping girls in school  
AGF (Abuja Goals Fund) *see* AGF  
alcohol  
problematic use of 239, 242–5  
taxation *see* alcohol taxation  
anthropometric outcomes 55  
beneficiaries of 105  
benefit-cost ratios 260–3  
and CBA (cost-benefit analysis) 108, 242–5  
CCT (conditional cash transfer) *see* CCT (conditional  
cash transfer)  
community mobilization *see* community mobilization  
cost-effectiveness 17–23, 242–5, 260  
criteria for 61–2  
cross-intervention benefits 347  
demand-side 55, 245  
effectiveness 17–23, 242–5  
evidence-based allocation strategy 17–18  
external validity of 294  
gender role perceptions/training *see* gender roles  
perception/training  
GS (general structure) 216–18  
HIV infection reduction 34–9, 255–9  
HIV reduction benefit-cost ratios 34–7, 41–2, 63–4,  
174  
HIV treatment issues 70  
and HIV vulnerability social drivers 239  
HIVNS (HIV-focused non-structural) 216–18, 221  
and hope 288–90  
HSS (health systems strengthening)  
and cost-benefit analyses 221  
objectives 186  
scale 219  
IDU 92–5  
IMAGE *see* IMAGE  
impact evaluations 50  
implementation time 219  
investment priorities 189  
keeping girls in school *see* keeping girls in school  
local diagnosis 289  
location-specific 15–17  
long-lasting 222  
and MSM 53  
Nobel Laureate Economist Expert Panel findings 337–8  
and orphan care costs 311  
pMTCT (mother-to-child transmission) 109–13, 118,  
121, 151, 160–6  
and population size 17  
potential behavioral responses 50–2  
potential beneficiaries 39–41  
pre-exposure chemoprophylaxis 53, 54  
preventative vs treatment 104–5  
prevention efficiency 52–3  
priority setting 220  
sexually transmitted infections 50  
Stepping Stones 246, 258–9  
stigma of HIV/AIDS 1, 4, 6, 20, 97, 238, 239, 240, 242,  
255, 265  
structural interventions 286  
target populations 220, 247, 248–9  
targeted approaches 53  
and technologies/strategies 329  
total costs per country 272–3  
transferable social policy 283–4



- treatment for prevention (test-and-treat) 12–14, 18, 19–20, 22–3, 25, 53–4, 166–8
- trusted interventions 19
- unit costs per country 272–3
- vulnerable populations 220
- investment approach to strategies 15, 17, 21
  - six program components 15
- iPrEx study 54
- IPV (intimate partner violence) 265
- irresponsible sexual behavior as HIV epidemic driver 285
  
- Jamison, Dean 7, 189
- Johri, Mira 5
  
- Karlan, Dean 191
- Kazianga, Harounan 6–7
- keeping girls in school 245, 251–2, 254, 258, 260–1, 267, 268, 269–70, 284, 293, 294, 343–4, 346, 347
- Kemron 51
- Kenya
  - alcohol tax 262–3
  - alcohol taxation 244
  - ART cures 51
  - development indicators 227
  - family planning unmet needs 165
  - health priority survey 230–1
  - HIV epidemic scale 65–6
  - HIV incidence/prevalence 12, 13, 66–7, 296–7
  - IDU (injecting drug use) interventions 92–5, 96–7
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - life insurance incentivization 296–7
  - male circumcision 23–5
  - Millennium Village Project (MVP) 247
  - needle-sharing infections 74
  - problems faced by government (Afrobarometer) 232
  - sexually transmitted HIV 11
  - unsafe medical injections 74
- Killingo, Bactrin 341, 342, 343
- Kilonzo, Nduku 341, 342–4, 345
- Kohler, Hans-Peter 4, 349
  
- labor ward screening 118–19
- laboratory infrastructure improvement intervention 186
- lack of knowledge as HIV epidemic driver 285
- Laniyan, Christiana 341, 342, 343, 344
- Lesotho
  - alcohol tax 262–3
  - blood transfusion infections 74
  - bush circumcisions 52
  - health worker shortage 196
  - HIV epidemic scale 65–6
  - HIV incidence/prevalence 12, 13, 29, 30, 34, 66–7, 196
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - needle-sharing infections 74
  - problems faced by government (Afrobarometer) 232
- sexually transmitted HIV 11
- unmet need for family planning 165
- liability and cost ratio 323
- Liberia
  - Abuja target 202
  - alcohol tax 262–3
  - HIV incidence/prevalence 13
  - key indicators 115–16
  - life expectancy with/without AIDS 162
- life expectancy 161, 169
- life insurance 6–7
  - incentivization 296–7
- life-cycle perspective 26, 30, 62
- life-year costs 145
- life-year values 137, 164, 170–1, 188–9
- monetization 226
- life-years gained 179–81, 188, 200, 307
- LiST software tool 78
- location-specific interventions 15–17
- LoveLife campaign 70
  
- McGreevey, William 5–6
- Madagascar
  - alcohol tax 262–3
  - health priority survey 230–1
  - HIV incidence/prevalence 13
  - key indicators 115–16
  - problems faced by government (Afrobarometer) 232
- Makhwapheni Campaign* 70–1
- Making Services Work for Poor People* 233
- malaria, as investment priority 189
- Malawi
  - alcohol tax 262–3
  - cash incentive programs 21, 57–8
  - CCTs (conditional cash transfers) 192–3, 245
    - keeping girls in school 245, 254, 258
  - development indicators 227
  - donor money corruption 231
  - family planning 197
  - Farm Input Subsidy Programme 247
  - GNI per capita 226–8
  - health priority survey 230–1
  - health workers 196, 228
  - HIV epidemic scale 65–6
  - HIV incidence/prevalence 13, 34, 196
  - HIV and sexual contact 14
  - key indicators 115–16
  - life expectancy 226–8
    - with/without AIDS 162
  - male circumcision 23–5
  - Millennium Village Project (MVP) 247
  - PBI (performance-based incentive) 192
  - problems faced by government (Afrobarometer) 232
  - SIHR (Schooling, Income, and HIV Risk) study 193
  - unmet need for family planning 165
  - Voices of the Poor* project 196
- male circumcision *see* MC



## 358 Index

- Mali  
 alcohol tax 262–3  
 HIV incidence/prevalence 13, 114–17  
 key indicators 115–16  
 problems faced by government (Afrobarometer) 232  
 mass media IC (information campaigns) 25–6, 34, 41–2, 49–50, 52–3, 62, 63, 70–1  
 maternal health and child survival 111  
 maternal mortality 197, 198, 202  
 Mauritania  
 HIV incidence/prevalence 13, 114–17  
 key indicators 115–16  
 Mauritius  
 alcohol tax 262–3  
 HIV incidence/prevalence 13, 114–17  
 IDU (injecting drug use) infection 92–5  
 key indicators 115–16  
 MBB (marginal budgeting for bottlenecks) 185, 203  
 Mbeki, President Thabo 234, 235  
 MC (male circumcision) 4, 12, 15, 18, 21, 22–5, 41–2, 49–50, 300, 301, 346  
 benefit-cost ratios 36–7, 40–1, 63–4, 339  
 bush circumcisions 52  
 cost-effectiveness of 58, 62  
 costs of 33  
 as high priority 348  
 infant 339, 348  
 and infection prevention 326  
 intervention efficiency 52–3  
 intervention requirements 39–41  
 key issues 69  
 lack of as HIV epidemic driver 285  
 long-term benefits 25–6, 62, 66, 68–9  
 Male Circumcision: Decision Makers' Program Planning  
 Tool (DMPPT) 18  
 neonatal 25, 52  
 uptake and resources 323  
 MDGs *see* Millennium Development Goals  
 Medecins Sans Frontiers 159  
 medical injections 4, 74, 81–5, 86, 102–3  
 medical male circumcision *see* MC  
 Mema wa Vijana intervention 255  
 men who have sex with men *see* MSM  
 Menberu, Retta 341, 343, 345  
 Merck vaccine failure 302  
 metaphorical language in social policy interventions 281–90  
 metaphors  
 and cost-effective analyses 281  
 inappropriate 281–8  
 risk behavior 284–6  
 structural drivers 284–6  
 unexamined 281–6  
 unrecognized 281  
 Mexico, conditional cash transfers 191, 254  
 microbicides and HIV risk 64, 71  
 microfinance schemes 21, 246, 247  
 Millennium Development Goals  
 failure to achieve 341  
 Goal 4 (reduce child mortality) 121–2  
 Goal 5 (improve maternal health) 121–2  
 Goal 6 (combat HIV/AIDS) 121–2, 242  
 Millennium Village Project (MVP) 247, 252  
 Mills, Anne 185  
 Mix Market platform 252  
 modes of transmission 66–7  
 Montaner, J. S. G. 69–70  
 moral hazard 146  
*More than good intentions* 191  
 most-valued persons 189–90  
 MOT (Modes of Transmission) model 81, 102, 103–4  
 mother-to-child transmission 4, 5, 74, 75, 77, 88–92, 160–6  
 anti-retroviral prophylaxis options 109–10, 121  
 AP (assessment paper) analysis 107, 108, 110–12  
 CBA (cost-benefit analysis) 108  
 CD4 screening 161  
 contraception 164  
 family planning 117, 161, 163–4  
 cost-effectiveness of 164  
 infant HIV exposure diagnosis 161  
 labor ward screening 118–19  
 maternal health and child survival 111  
 maternal mortality 197  
 multiplex POC (point-of-care) diagnostic tests 119–21  
 non-health facility births 119  
 pMTCT cascade 107, 117, 118, 122  
 potential HIV rates in sub-Saharan Africa 163  
 prevention (pMTCT) 77, 78, 79, 91–2, 97, 103, 105, 107, 108, 169–70, 347–8  
 analytic timeframe 111–12  
 benefit-cost reduction 174–5, 342–3  
 CD4 cell count 110–12, 172  
 and Civil Society Panel 342–3  
 comprehensive vs narrow approach to 108–9  
 costs  
 and health system infrastructure 113  
 and HIV prevalence 113  
 emerging technology 122  
 forward transmission impact 107, 112  
 full benefits definition 161  
 and health system infrastructure 117–18  
 intervention options 109–12, 113, 151  
 key challenges 113–18  
 Nobel Laureate Economist Expert Panel findings 342–3  
 pre-pregnancy 164–6  
 scaling up 346, 347  
 services increase requirements 121–2  
 solutions 118–21  
 therapeutic options 111, 112, 121  
 treatment evaluation 172  
 treatment targets 156  
 treatment vs family planning 163–4  
 primary prevention 164

- screening tests 161
- in sub-Saharan Africa 74, 107, 163
- testing and counseling 161
- treatment for prevention (test-and-treat) 12–14, 18, 19–20, 22–3, 25, 53–4, 166–8
- WHO Option A strategies 107–8
- Mozambique
  - alcohol tax 262–3
  - development indicators 227
  - health worker shortage 196
  - HIV epidemic scale 65–6
  - HIV incidence/prevalence 13, 34, 39–40, 196
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - male circumcision 40–1
  - problems faced by government (Afrobarometer) 232
  - unmet need for family planning 165
- MSM (men who have sex with men) 4, 53, 66–7, 69, 238
- MTCT *see* mother-to-child transmission
- multiple partners 126, 159
- multiplex POC (point-of-care) diagnostic tests 119–21
- Namibia
  - alcohol tax 262–3
  - health priority survey 230–1
  - HIV incidence/prevalence 13, 34
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - male circumcision 23–5
  - problems faced by government (Afrobarometer) 232
  - unmet need for family planning 165
- NAT (nucleic acid amplification testing) 86
- national epidemics 283
- national strategies xx
- National Technical Teams (NTTs) 345
- Natrass, Nicoli 6
- needle-exchange 105
- neonatal circumcision 25, 52
- Nevaprine 126, 161–2
- Niger
  - alcohol tax 262–3
  - blood supply testing 86
  - HIV incidence/prevalence 13, 114–17
  - key indicators 115–16
- Nigeria
  - alcohol tax 262–3
  - development indicators 227
  - health system capacity 226–8
  - HIV epidemic scale 65–6
  - HIV incidence/prevalence 13
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - problems faced by government (Afrobarometer) 232
  - unmet need for family planning 165
- Nobel Laureate Economist Expert Panel 337–8
- non-sexual HIV transmission prevention
  - AIDS impact model 78–9
  - analysis methods 102, 103–4
  - benefits calculation 76–8
  - benefits summary 96
  - blood transfusions 74, 86–8, 102–3
  - Goals Model/Goals Express 79–81
  - HIV infections averted model 78
  - injecting drug users 92–5
  - medical injections 4, 74, 81–5, 86, 102–3
  - mother-to-child transmission 4, 5, 74, 88–92, 169–70
  - multi-country analysis options/limitations 102–3
  - recommendations 96–7
  - resource allocation equity 105
- NVP (Nevirapine) program 126, 161–2
- O&G model of infections 152–3
  - and high-risk groups 155
  - infection flows 155
  - with interventions 153–4
  - transmission mechanism specification 154–5
- Odumbe, Ken 341, 342, 345
- OIs (opportunistic infections) 76–7, 78, 89, 307, 311
- One Million Community Health Workers* 195
- operations research intervention 186
- opiate substitute therapies 105
- oppression illness 287
- oral anti-retrovirals 301
- oral prophylaxis 238
- orphan care costs 311
- OST (opioid substitution therapy) 75, 105
- Over, Mead 5, 173–4, 178–82, 347–8
- Padian, N. S. 2
- patient transport intervention 186
- PBI (performance-based incentive) 192
- Pearl Omega 51
- Peer Group IC (information campaigns) 25–6, 34, 41–2, 49–50, 52–3, 62, 63
- PEPFAR (Presidential Emergency Plan for AIDS Relief) 61, 67, 92–5, 179, 182, 184–6, 189, 213, 214–15, 217, 255
- pilot studies, external validity of 294
- Piot, Peter xx
- Platform for Health System Strengthening 195
- pMTCT *see* mother-to-child transmission
- POC (point-of-care) diagnostic tests 119–21
- Poor Economics, a Radical Rethinking of the Way to Fight Global Poverty* 191
- poverty as HIV epidemic driver 285, 287
- pre-exposure prophylaxis 154, 301
  - chemoprophylaxis 53, 54, 58
- Prescott, Edward C. 337–8
- preventative interventions 104–5
- Prevention of Non-sexual Transmission Assessment Paper 169–70
- primary health care, HIV treatment integration with 214–15
- primary infection prevention 159
- production function model 295

## 360 Index

- program enablers 194–5  
 promiscuous sexual behavior as HIV epidemic driver 285  
 Protocol G 313
- QALYs (quality-adjusted life years) 21–2, 75, 175–6, 349
- RAPID software tool 78  
 Rasmussen, Prime Minister Anders Fogh 2  
 RBF (results-based financing) 184  
 RBF (results-based funding) programs 202–3  
 RCTs (randomized controlled trials) 18–19, 24, 69  
   hope and intervention studies 289  
   role of 64–5  
   and spillover benefits 145–6  
 Remme, Michelle 6  
 research intervention 186  
 RESPECT study 57, 193  
*RethinkHIV* project 11, 21–2, 23, 25–6, 41, 52, 61–2, 65, 74, 76, 77, 104, 108–9, 121–2, 137, 151, 155, 163, 164, 170–1, 174, 175–6, 218, 233, 238, 299, 300, 328, 342  
 risk behavior 284–6  
 risk compensation 146  
 risk ecology 285, 286  
 risk environments 285  
   and individual behavior 286  
 risk-taking behavior patterns 130–1, 133, 146  
 risk-taking behavior research 56  
 RNM (Resource Needs Model) 18  
 Rome International AIDS Conference 238  
 RP (revealed preference) approach 170  
 Rush Foundation 2, 7, 8  
 Rwanda  
   Abuja target 202  
   alcohol tax 262–3  
   HIV awareness 192  
   HIV incidence/prevalence 13  
   key indicators 115–16  
   life expectancy with/without AIDS 162  
   life insurance incentivization 296–7  
   male circumcision 23–5, 325  
   OIs (opportunistic infections) 76–7, 78  
   unmet need for family planning 165
- S-I (susceptible-infection) transmission system 152–5  
 safe blood transfusions *see* blood transfusions  
 safe medical injections 81–6  
   precautions intervention 186  
 Salomon, Joshua 7  
 Schelling, Thomas C. 337–8  
 schistosomiasis 97  
 schoolgirls *see* keeping girls in school  
 secondary infection prevention 159, 311  
 Sendai virus 313  
 Senegal  
   alcohol tax 262–3  
   HIV incidence/prevalence 13, 114–17  
   key indicators 115–16  
   problems faced by government (Afrobarometer) 232  
   sexual abstinence 68, 255  
   sexual abstinence month 4, 71  
   sexual behavior, different contexts 283  
   sexual health, and CM (contingency management) 55–6  
   sexual infections 11, 41–2, 49  
   sexual practices, cultural 285  
   sexual relations  
     frequency 193  
     and HIV prevention 11–17, 20, 33, 34–7, 41–2  
     risk-taking behavior 56–7  
     *see also* keeping girls in school  
   sexually transmitted diseases (STDs)  
     and alcohol 243  
     HIV 11, 18, 32, 50–2, 63–4, 66–7, 74, 169–70, 238, 300, 339  
     prevention basics 67–8  
     *see also* non-sexual HIV transmission  
   sexually transmitted infections (STIs) 11, 41–2, 49, 50, 65, 300, 339  
   as HIV epidemic drivers 285  
 Sierra Leone  
   alcohol tax 262–3  
   HIV incidence/prevalence 13  
   key indicators 115–16  
 SIHR (Schooling, Income, and HIV Risk) study 193  
 simulated scenarios in ART (anti-retroviral treatment) 135–7  
 Smith, Vernon L. 337–8  
 Snyder, Richard 288  
 social conditions, embodiment of 287–8  
 social intervention, and hope 288–90  
 social policy interventions 281–90  
   Nobel Laureate Economist Expert Panel findings on 339–40  
 Somalia, key indicators 115–16  
 Somaliland, *Voices of the Poor* project 196  
 South Africa  
   alcohol tax 262–3  
   alcohol taxation 243  
   ART program 217  
   development indicators 227  
   GNI per capita 226–8  
   health system capacity 226–8  
   HIV epidemic scale 65–6  
   HIV incidence/prevalence 12, 13  
   HIV testing 195  
   HIV/AIDS disease statistics 200  
   HIV/AIDS stigma 248–9  
   IDU (injecting drug use) intervention 92–5, 96–7  
   IMAGE (Intervention with Microfinance for AIDS and Gender Equity) 21, 246, 247  
   key indicators 115–16  
   life expectancy 226–8  
     with/without AIDS 162  
   male circumcision 23–5

- Medecins Sans Frontiers project 159
- microfinance schemes 247
- PEPFAR-funded interventions 255
- problematic alcohol use 242
- problems faced by government (Afrobarometer) 232
- TAC (Treatment Action Campaign) 234–5
- unmet need for family planning 165
- voluntary HIV testing and counseling uptake at community level 248
- Spectrum policy models 78–9, 89–90, 93, 96–7, 102, 103–4
- spillover benefits 145
- SROI (Social Return on Investment) 248–9
- SSA *see* sub-Saharan Africa
- stand-alone HIV programs 215
- standard dynamic model of infections 152
  - with interventions 153–4
- statistical life value 189–90
- Stavudine 126, 174
- STDs *see* sexually transmitted diseases
- Stein, Zena 64
- Steinberg, Jonny 234
- Stepping Stones 246, 258–9
- stigma of HIV/AIDS 1, 4, 6, 20, 97, 238, 239, 240, 242, 248–9, 255, 265
- STIs (sexually transmitted infections) 50, 65, 66–7
- Stover, John 5
- strategies 329
- Strengthening Health Systems 5–6
- stressors 284
- structural drivers metaphor 284–6
- structural interventions 286, 287
- sub-Saharan Africa
  - Abuja Goals Fund (AGF) *see* AGF
  - age-specific survival 29, 30
  - AIDS funding 342
  - AIDS spending and health systems strengthening (HSS) 186–7
  - AIDS vaccine
    - costs 306, 322–3
    - and epidemic future 324
  - ART (anti-retroviral treatment) xix
    - benefits 184
    - coverage 77–8
  - BCC (behavioral change communication) 16
  - behavioral strategies 14–15
  - benefit-cost ratios for ARV 178–82
  - benefits of HIV prevention 306–8
  - blood supply testing 86
  - CCT programs
    - effectiveness 55
    - and keeping girls in school 220–2, 245, 251–2, 254, 258, 293, 294, 343–4
  - Civil Society Panel *see* Civil Society Panel
  - community health workers
    - costs of 196–7
    - deployment 183
  - community mobilization programs 34
  - cost-effectiveness 11, 20, 104
  - cryptococcal antigen (CRAG) test 199–201
  - cryptococcal meningitis 183, 199–201
  - death averted 188–9, 194, 203, 204
  - development indicators 227
  - family planning *see* family planning
  - female sex workers 296–7
  - financial incentives for 5–6
  - gender role perceptions 239, 240, 246–7
  - GNI per capita 75–6
  - HIV incidence in xix, 1, 12, 19, 29, 30, 34, 39–41, 181, 238
  - HIV transmission 238
    - models 79–81, 131–3
  - HIV in women 172–3
  - HIV/AIDS disease statistics 200
  - HIV/AIDS social policy interventions 281–90
  - HIV/AIDS solutions 41–2
  - HTC, home-based 25
    - ICD (infectious and communicable diseases) 188
  - incentivizing adults 296–7
  - income per capita 306
  - increased health spending 188
  - infant infections 198
  - infections and injections 83
  - interventions *see* interventions
  - keeping girls in school *see* keeping girls in school
  - key indicators 115–16
  - labor ward screening 118–19
  - life expectancy 162, 184
  - life-year values 137
  - male circumcision 12, 23–5, 62
  - maternal mortality 197, 198
  - modes of transmission 66–7
  - mother-to-child transmission 74, 107
  - Nobel Laureate Economist Expert Panel findings 337–8
  - OIs (opportunistic infections) 76–7, 78
  - pMTCT benefit-cost ratios 160–1
  - pMTCT options 112–13
  - pMTCT services increase requirements 121–2
  - potential beneficiaries of intervention 39–41
  - potential HIV rates 163
  - pre-exposure chemoprophylaxis 53, 54, 58
  - RethinkHIV* project 11
  - safe blood transfusions 86–8
  - screening tests 161
  - sexual relations and HIV prevention 11–17
  - sexually transmitted HIV 11
  - Strengthening Health Systems 5–6
  - testing and counseling 161
  - treatment cost per person/year 135
  - UNAIDS spending proposal 205
  - universal testing, informing, and counseling 183
  - unmet need for family planning 165
  - women and HIV 172–3
  - substance abuse, as HIV epidemic driver 285
  - Sudan, unmet need for family planning 165
  - supply chain management 323

## Swaziland

- alcohol tax 262–3
- ARV requirement 174
- blood transfusion infections 74
- HIV epidemic scale 65–6
- HIV incidence/prevalence 12, 13, 29, 30, 34, 66–7, 114–17
- key indicators 115–16
- life expectancy with/without AIDS 162
- male circumcision 23–5
- resources allocated to 15–17
- sexually transmitted HIV 11
- unmet need for family planning 165
- unsafe medical injections 74

synergies with development sectors 188–9

TAC (Treatment Action Campaign) 234–5

## Tanzania

- Abuja target 202
  - alcohol taxation 244, 262–3, 296
  - blood supply testing 86
  - cash incentive programs 57–8
    - CCTs (conditional cash transfers) 245, 296
  - condoms 170
  - cost-effectiveness of HIV prevention 5, 73
  - development indicators 227
  - HIV epidemic scale 65–6
  - HIV incidence/prevalence 13, 283
  - HIV/AIDS stigma 248–9
  - IDU (injecting drug use) intervention 92–5, 96–7
  - intervention studies 170–1
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - life insurance incentivization 296–7
  - listed HIV epidemic drivers 285
  - Mema kwa Vijana intervention 255
  - problems faced by government (Afrobarometer) 232
  - RESPECT study 193
  - sexually transmitted infections 50
  - unmet need for family planning 165
  - voluntary HIV testing and counseling uptake at
    - community level 248
  - VSL (Value of a Statistical Life) approach 170–1
- Tanzanian AIDS Commission 285
- Tanzanian epidemic 283
- targeting strategy 312
- TASO (AIDS Support Organization) 234–5
- technologies 329
- temporary sexual relationships as HIV epidemic driver 285
- tenofovir 126
- test-and-treat strategy *see* ART
- Thai RV144 vaccine 303, 326
- Thematic Panel Discussion 214
- Togo
- alcohol tax 262–3
  - blood supply testing 86
  - HIV incidence/prevalence 13

key indicators 115–16

life expectancy with/without AIDS 162

topical anti-retrovirals 301

topical microbicides 238

transferable social policy interventions 283–4

transmission susceptibility and income inequality 287

Treatment 2.0 Initiative 5, 174, 179

treatment interventions 104–5

treatment as prevention 166–8, 171–2

treatment resources vs stated goals 213–14

treatment unit costs 133–5

TRIPS (Trade-Related Intellectual Property Rights)
 

- agreements 168

Tshabalala-Msimang, Manto 234

tuberculosis as investment priority 189

## Uganda

- and Abuja Goals Fund (AGF) 207
  - alcohol tax 262–3
  - blood transfusion infections 74
  - CCTs (conditional cash transfers) 245
  - development indicators 227
  - HIV in couples 126
  - HIV epidemic scale 65–6
  - HIV incidence/prevalence 13, 66–7, 81, 324
  - HIV/AIDS stigma 248–9
  - infection age 307
  - injection infections 81
  - interventions, local diagnosis of 289
  - key indicators 115–16
  - life expectancy with/without AIDS 162, 307
  - Masaka intervention 255
  - microfinance schemes 247
  - OIs (opportunistic infections) 76–7, 78
  - PEPFAR-funded interventions 255
  - problems faced by government (Afrobarometer) 232
  - sexually transmitted HIV 11
  - sexually transmitted infections 50
  - TASO (AIDS Support Organization) 234–5
  - unmet need for family planning 165
- UNAIDS 185–6, 188–9, 205, 235–6, 346
- cost of saving life 205–6
  - founding of 61
  - improved investment approach 194–5
  - International Group on Analysis of Trends in HIV
    - Prevalence and Behaviors in Young People in
      - Countries most Affected by HIV (2010) 19
  - investment returns 188
  - and male circumcision 62
  - modes of transmission 66–7
  - program enablers 194–5
- UNAIDS Global Plan 90
- UNAIDS Investment Framework analysis 90
- UNAIDS MOT (Modes of Transmission) model 81
- UNAIDS Strategy (2011–2015) 14–15, 20
- UNAIDS (United Nations Joint Programme on HIV/AIDS)
  - 108–9

- UNDP (Joint United Nations Programme on HIV/AIDS) 346
- unexamined metaphors 281–6
- UNGASS 189
- unintended pregnancies 197
- unit costs per country 272–3
- United Nations
  - General Assembly Political Declaration on HIV/AIDS xix, 74
  - Security Council Resolution on HIV/AIDS xix
- United Nations High-Level Meeting on AIDS, Thematic Panel Discussion 214
- United Nations Non-Communicable Disease Summit (2011) 61
- United States, HIV prevalence 153
- universal HIV testing 183, 191–2, 206
  - adults 193
- universal precautions intervention 186
- vaccine research and development 7, 299–312, 321–7
  - accomplishments to date 300–1
  - annual investment in 303–5, 321
  - anti-retroviral therapy 330
  - benefit-cost analysis 304–9
    - of accelerating 309–12
    - continued investment 308–9
  - benefit-cost ratios 330
  - demand creation costs 323
  - development history 302–4
  - funding sources 300
  - infections averted benefits 308
  - investment priorities 328–9
  - new technologies 328–9
    - investments 334
- Nobel Laureate Economist Expert Panel findings on 337–9
- operational protocols 302
- and productivity levels 311
- prospects 302–4
- R&D 300–4
- research agenda 301–2
- research developments source 313
- secondary infection prevention 311
- and social value 330
- spending 300
- varying average costs 294–5
- Vassall, Anna 6
- VCT (voluntary counseling and testing) *see* HTC
- Vesicular Stomatitis Virus 313
- viral load
  - and HIV risk 126, 151
  - monitoring 179
- Voices of the Poor* project 196
- VSL (Value of Statistical Life) approach 170–1
- Watts, Charlotte 6
- Whiteside, Alan 4
- WHO (World Health Organization)
  - on alcohol taxation 243
  - Options 5, 162–3
  - program 162
- women living with HIV, unintended pregnancies 197
- World Bank
  - decline in benefit-cost analysis 190
  - health funding evaluation 233, 235–6
  - results-based funding (RBF) programs 202–3
  - structural adjustment lending 231–3
  - Voices of the Poor* 196
  - World Development Report 1993, Investing in Health* 203
- WTP (willingness to pay) 170–1
- ZAC (Zanzibar AIDS Commission) 283
- Zambia
  - Abuja target 202
  - alcohol tax 262–3
  - development indicators 227
  - health priority survey 230–1
  - health worker shortage 196
  - HIV epidemic scale 65–6
  - HIV incidence/prevalence 12, 13, 34, 66–7, 196
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - life insurance incentivization 296–7
  - male circumcision 23–5
  - OIs (opportunistic infections) 76–7, 78
  - problems faced by government (Afrobarometer) 232
  - sexually transmitted HIV 11
  - unmet need for family planning 165
  - Voices of the Poor* project 196
- Zaric, G. S. 295
- ZDV (Zidovudine) program 89, 162–3, 175
- zero uptake
  - and benefit-cost ratios 151
  - counterfactual 135, 136
  - simulation results 139
- Zimbabwe
  - alcohol tax 262–3
  - development indicators 227
  - health priority survey 230–1
  - HIV epidemic scale 65–6
  - HIV incidence/prevalence 12, 13, 19, 301, 324
  - HIV/AIDS stigma 248–9
  - key indicators 115–16
  - life expectancy with/without AIDS 162
  - male circumcision 23–5
  - maternal/infant life expectancy 111
  - problems faced by government (Afrobarometer) 232
  - unmet need for family planning 165
  - voluntary HIV testing and counseling uptake at community level 248
- Zuma, Jacob 195